Company intelligence / Profile preview

Royalty Holders

New York, New York, United States

Ownership: Private
Employees: ~35
Development stage: Other

Overview

Royalty Pharma owns partial or full royalty interests in 45+ commercial therapies, including blockbusters such as Kalydeco, Imbruvica, Xtandi, Tysabri, Symdeko, Trikafta, and Januvia. The royalty portfolio generates over $2.6 billion in annual revenue and covers multiple therapeutic areas. Royalty Pharma does not develop drugs itself, but funds innovation and asset development by purchasing royalty interests from innovator institutions and companies.

Therapeutic areas: ImmunologyEndocrinologyPulmonologyInfectious DiseasesNeurologyRare DiseasesOncology
Modalities: Small moleculeBiologicAntibodyRNA therapyCell therapy
Industry: Investors

Partnerships

Vertex PharmaceuticalsAbbViePfizerBiogenGilead SciencesJohnson & JohnsonNovartisBayerTakedaRocheSanofi

Beyond the preview

Go deeper on Royalty Holders.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Royalty Holders.

Explore the full profile